Trial Information
Inclusion Criteria:
- Hodgkin Lymphoma (histologically proven)
- CS (PS) IIB with one or both of the risk factors:
- bulky mediastinal mass (> 1/3 of maximum transverse thorax diameter)
- extranodal involvement
- CS (PS) III, IV
- Written informed consent
Exclusion Criteria:
- Leucocytes < 3000/µl
- Platelets < 100000/µl
- Hodgkin´s lymphoma as "composite lymphoma"
- Activity index (WHO) < grade 2
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Progression Free Survival
Outcome Time Frame:
5 years
Safety Issue:
No
Principal Investigator
Andreas Engert, Prof.
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Cologne
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
HD18
NCT ID:
NCT00515554
Start Date:
May 2008
Completion Date:
Related Keywords:
- Hodgkins Lymphoma
- Hodgkin lymphoma
- PET
- advances stages
- Rituximab
- Hodgkin Disease
- Lymphoma